FLUTAZOLAM

Details

Stereochemistry	RACEMIC
Molecular Formula	C19H18ClFN2O3
Molecular Weight	376.809
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OCCN1C2=CC=C(Cl)C=C2C3(OCCN3CC1=O)C4=CC=CC=C4F

InChI

InChIKey=WMFSSTNVXWNLKI-UHFFFAOYSA-N

InChI=1S/C19H18ClFN2O3/c20-13-5-6-17-15(11-13)19(14-3-1-2-4-16(14)21)22(8-10-26-19)12-18(25)23(17)7-9-24/h1-6,11,24H,7-10,12H2

HIDE SMILES / InChI

Molecular Formula	C19H18ClFN2O3
Molecular Weight	376.809
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://med.sawai.co.jp/file/pr22_1083.pdf

Flutazolam is a benzodiazepine derivative developed in Japan by Mitsui. The drug is marketed under the name Coreminal and used for the treatment of gastrointestinal disorders. The mechanism of flutazolam action is due to activation of GABA-A receptors as it has affinity to the benzodiazepine binding sites.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
GABA-A receptor; benzodiazepine site 38 Target ID: CHEMBL2109243 Sources: http://med.sawai.co.jp/file/pr22_1083.pdf	Partial Agonist 297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Gastrointestinal disorders 94 Sources: http://med.sawai.co.jp/file/pr22_1083.pdf	Palliative		Approved 8583	COREMINAL Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
0.014 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/300119_1124024C1035_2_070_1F.pdf#page=23	12 mg single, oral dose: 12 mg route of administration: Oral experiment type: SINGLE co-administered:		FLUTAZOLAM serum	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
0.068 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/300119_1124024C1035_2_070_1F.pdf#page=23	12 mg single, oral dose: 12 mg route of administration: Oral experiment type: SINGLE co-administered:		FLUTAZOLAM serum	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

PubMed

Title	Date	PubMed
Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays.	2017-04	27366870
Simultaneous determination of twelve benzodiazepines in human serum using a new reversed-phase chromatographic column on a 2-microns porous microspherical silica gel.	1996-06-28	8832439
[Studies on the clinical significance concerning the changes in serum pepsinogen-I and gastrin levels in aged patients with chronic gastritis].	1988-03	2898425
[The behavior of 1,4-benzodiazepine drugs in acidic media. IX. Effect of hydrolyzate of flutazolam on the central nervous system].	1987-10	2894449
The behavior of 1,4-benzodiazepine drugs in acidic media. V. Kinetics of hydrolysis of flutazolam and haloxazolam in aqueous solution.	1986-01	2870816
[Psychopharmacological effects of flutazolam (MS-4101) (author's transl)].	1978-11	750333

Sample Use Guides

In Vivo Use Guide

The usual adult dose is 12 mg administered 3 times/day.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:08:46 GMT 2025` Edited by `admin` on `Mon Mar 31 18:08:46 GMT 2025`
Record UNII	5G2K7O5D8S
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

COREMINAL

Preferred Name

English

FLUTAZOLAM

Official Name

English

FLUTAZOLAM [MI]

Common Name

English

flutazolam [INN]

Common Name

English

10-CHLORO-11B-(O-FLUOROPHENYL)-2,3,7,11B-TETRAHYDRO-7-(2-HYDROXYETHYL)OXAZOLO(3,2-D)(1,4)BENZODIAZEPIN-6(5H)-ONE

Common Name

English

FLUTAZOLAM [MART.]

Common Name

English

FLUTAZOLAM [JAN]

Common Name

English

Flutazolam [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1012